PSCA抗体;PSCA Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using PSCA mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of PC-3 cells using PSCA mouse mAb (green) and negative control (red).    

  
  

The prostate stem cell antigen (PSCA) is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein first identified in prostate cancer. It belongs to the Ly-6/thy-1 family of cell membrane proteins and is overexpressed in various cancers, including prostate, pancreatic, bladder, and gastric malignancies, while showing limited expression in normal tissues. This tumor-restricted expression makes PSCA a promising target for diagnostic and therapeutic applications.

PSCA antibodies are engineered to specifically bind PSCA epitopes, enabling targeted approaches such as cancer cell detection, drug delivery, and immunotherapy. Monoclonal antibodies (mAbs) against PSCA have been explored for imaging tumors, delivering cytotoxic agents via antibody-drug conjugates (ADCs), or engaging immune cells through bispecific formats. Additionally, PSCA-targeted CAR-T cells and immunotoxins are under preclinical and clinical evaluation, showing potential in eradicating PSCA-positive tumors.

Despite its promise, challenges remain, including heterogeneity in PSCA expression across tumors, potential off-target effects, and resistance mechanisms. Ongoing research focuses on optimizing antibody specificity, combination therapies, and biomarker-driven patient stratification to enhance clinical outcomes. PSCA antibodies thus represent a versatile tool in advancing precision oncology.

(Word count: 199)